Some points that took my interest:
1) Placing the NASDAQ listing on ice (does not fuss me)
2) Initiating an internal review to roadmap milestones and progress (no doubt initiated by the two new executive recruits). This renewed focus is good in my opinion.
3) A canine exploratory study is underway with initial results due in May
4) Epichem revenue has managed to turn the company into a cashflow positive position for the quarter! (even after the $406K R&D refund is excluded). Significant.
5) Confirmation that Epichem revenues and customer base are expanding
Ann: Appendix 4C - Quarterly Report & Company Update - March 2017, page-2
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.010(4.88%) |
Mkt cap ! $104.6M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.5¢ | 20.5¢ | $244.1K | 1.163M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71981 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 84173 | 3 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |